INTRODUCTION {#SEC1}
============

The interpretation of the function of genomic variants, particularly in non-coding regions, is a major challenge for the genetic dissection of complex diseases such as cancer ([@B1]). Genome-wide association studies (GWAS) have identified numerous genetic loci that influence the risk of human cancer ([@B2],[@B3]), but most of these loci are located in non-coding regions and are without clear molecular mechanisms that contribute to the phenotypic outcome. Previous studies considered a diverse set of functional regions, including miRNA binding sites, protein modification sites and transcription factor binding sites ([@B4],[@B5]). However, the link between variants and epigenetic signals involved in the regulation of key biological processes has been largely overlooked.

As a major epigenetic mechanism that directs gene expression, DNA methylation plays a key role in the regulation of crucial biological and pathological processes ([@B6]). Aberrant DNA methylation is frequently observed in various cancers ([@B7]) and represents an attractive biomarker and therapeutic target ([@B8],[@B9]). Increasing evidence indicates that single-nucleotide polymorphisms (SNPs) contribute to tumor initiation, progression and prognosis by influencing DNA methylation levels ([@B10],[@B11]). Therefore, DNA methylation may be an important molecular-level phenotype that links a genotype with the trait of a complex disease. It is fundamentally vital to build a public data repository to identify SNPs that significantly affect DNA methylation levels, i.e. methylation quantitative trait loci (meQTL). Recent methodological advances allow for genome-wide screening of meQTLs in different tissues, including blood ([@B12]), lung ([@B13]) and brain ([@B14]). However, no database has been developed to systematically analyze meQTLs across multiple cancer types.

The Cancer Genome Atlas (TCGA) provides genome-wide genotype data and DNA methylation data for ∼10 000 cancer samples, making it possible to systematically conduct meQTL analysis across cancer types. We identified millions of meQTLs across 23 cancer types and have made them available for browsing, searching and downloading through Pancan-meQTL (<http://bioinfo.life.hust.edu.cn/Pancan-meQTL/>), a database for systematic evaluation of the effects of genetic variants on DNA methylation across diverse cancer types.

DATA COLLECTION AND PROCESSING {#SEC2}
==============================

Genotype data collection, imputation and processing {#SEC2-1}
---------------------------------------------------

We downloaded genotype data (level 2) from TCGA data portal (<https://portal.gdc.cancer.gov/>) (Figure [1A](#F1){ref-type="fig"}). We kept 7735 samples with both genotype data and methylation data. We then combined colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ) as colorectal cancer (CRC) ([@B15]) and removed cancer types with sample size \<100 primary tumor samples. Thus, for further analysis, we had 7242 samples across 23 cancer types. We performed genotype imputation and filtering per cancer type as described in our previous study ([@B16]). After imputation and quality filtering, on average, 4 318 218 genotypes per cancer type were included in the meQTL analysis.

![Data collection, processing and database construction. Pancan-meQTL collected the genotype, methylation and clinical data from TCGA to evaluate the effects of SNPs on methylation levels. For each cancer type, the data were processed using a series of filtering and quality control steps. Four datasets, *cis*-meQTLs, *trans*-meQTLs, survival-meQTLs and GWAS-meQTLs, are included in the database.](gky814fig1){#F1}

Methylation data collection and processing {#SEC2-2}
------------------------------------------

Methylation beta values (level 3) obtained from TCGA data portal (<https://gdc-portal.nci.nih.gov/>) were measured by the Illumina Infinium HumanMethylation450 BeadChip array, which contained 485 512 probes for each sample. Due to the specific nature of methylation patterns on sex chromosomes ([@B17]), we focused on autosomes. In each cancer type, probes were filtered by the following criteria: (i) methylation beta value missing rate \> 0.05, (ii) mapping to multiple locations on the genome ([@B18]) and (iii) containing known SNP (1000 Genome Phase3 ([@B19]), MAF \> 0.01) at CpG sites ([@B20],[@B21]) (Figure [1B](#F1){ref-type="fig"}). On average, 369 244 high-quality methylation probes per cancer type were used for analyses. To minimize the effects of outliers on the regression scores, the values for each probe across samples per cancer type were transformed into a standard normal distribution based on rank ([@B17],[@B22],[@B23]).

Covariates {#SEC2-3}
----------

To correct for known and unknown confounders and increase the sensitivity of our analyses, we included several covariates. The top five principal components calculated by smartpca in the EIGENSOFT program ([@B24]) were included to control for ethnicity differences. To remove hidden batch effects and other confounders in the methylation data, we used PEER software ([@B25]) to select the first 15 PEER factors from the methylation data as covariates. We included the common confounders of age, sex, and tumor stage as additional covariates ([@B21],[@B23],[@B26]).

Identification of meQTLs {#SEC2-4}
------------------------

Identification of meQTL is straightforward that to test whether individuals carrying different genotypes show different methylation levels ([@B17],[@B20],[@B27],[@B28]). For each cancer type, we performed linear regression with MatrixEQTL ([@B29]) to determine the effects of genetic variation on methylation levels. We calculated the pairwise associations between each SNP and CpG site. We used HumanMethylation450 BeadChip array annotation to extract the location (hg19) of methylation probes. We downloaded the SNP location (hg19) from dbSNP (<https://www.ncbi.nlm.nih.gov/projects/SNP/>). We defined meQTLs as SNPs with false discovery rates (FDRs) calculated by MatrixEQTL \<0.05 and the absolute value of correlation coefficient (*r*) ≥0.3. If the SNP was within 1 Mb from the probe location ([@B22]), we denoted it as *cis*-meQTL; and if the SNP was beyond that point, we denoted it as *trans*-meQTL.

Identification of survival-associated meQTLs {#SEC2-5}
--------------------------------------------

To prioritize promising meQTLs, we identified meQTLs that may be associated with patient survival times. We downloaded the clinical data, including patient overall survival times, from TCGA data portal (<https://gdc-portal.nci.nih.gov/>). For each meQTL, we used the log-rank test to examine the association between genotypes and patient overall survival times. We plotted Kaplan--Meier (KM) curves to show the survival times for individuals carrying different genotypes. We defined meQTLs with FDR \<0.05 as survival-meQTLs.

Identification of meQTLs in GWAS regions {#SEC2-6}
----------------------------------------

Risk SNPs identified in GWAS studies were downloaded from GWAS catalog (<http://www.ebi.ac.uk/gwas/>) ([@B2]). GWAS linkage disequilibrium (LD) regions were extracted from SNAP (<https://personal.broadinstitute.org/plin/snap/ldsearch.php>) ([@B30]) with parameters (SNP data set: 1000 Genomes Pilot 1; LD *r*^2^ threshold: 0.5; population panel: CEU; distance limit: 500 kb). The meQTLs that overlapped with GWAS tagSNPs and LD SNPs were identified as GWAS-meQTLs.

Enrichment analysis {#SEC2-7}
-------------------

To assess the enrichment of meQTLs in DNA regulatory elements and GWAS loci, we generated a control data set of non-meQTL SNPs with minor allele frequency (MAF) and distance matched to the set of meQTLs for each cancer type. We downloaded transcription factor binding sites (TFBSs) of related ENCODE cell lines from the UCSC genome browser, and extracted cancer-specific GWAS loci from GWAS catalog. Enrichment analyses of meQTLs were performed by two-tailed Fisher\'s exact test with the following 2 × 2 table: columns; meQTL SNPs and non-meQTL SNPs, rows; SNPs within and not within the TFBSs/GWAS loci.

DATABASE CONTENT AND USAGE {#SEC3}
==========================

Samples in Pancan-meQTL {#SEC3-1}
-----------------------

Pancan-meQTL included 23 cancer types with sample size ≥100 in TCGA, covering 7242 tumor samples. The sample size of each cancer type ranged from 103 in skin cutaneous melanoma (SKCM) to 664 in breast invasive carcinoma (BRCA) (Table [1](#tbl1){ref-type="table"}). For the genotype data, we obtained a median of 4 487 756 SNPs for each cancer type after imputation and quality control, ranging from 2 721 411 for BRCA to 5 121 896 for acute myeloid leukemia (LAML). For the methylation data, there were, on average, 384 903 probes for each cancer type after probe filtering and quality control. The range was from 380 594 for CRC to 385 618 for testicular germ cell tumors (TGCT).

###### 

Overview of samples and meQTLs in Pancan-meQTL

                                                                                                     *Cis*     *Trans*                             
  ------ ------------------------------------------------------------------ ----- -------- --------- --------- --------- -------- -------- ------- -------
  BLCA   Bladder urothelial carcinoma                                       405   384903   4182865   502774    8136      301392   216341   46165   51295
  BRCA   Breast invasive carcinoma                                          664   384084   2721411   340881    7289      203391   47355    1804    31118
  CESC   Cervical squamous cell carcinoma and endocervical adenocarcinoma   290   383425   4289322   531458    11284     318082   212025   48741   46185
  CRC    Colon adenocarcinoma + Rectum adenocarcinoma                       354   380594   3879590   555556    10781     316517   185943   40872   55402
  ESCA   Esophageal carcinoma                                               173   382712   4357977   408020    15726     260629   21790    5427    13297
  HNSC   Head and neck squamous cell carcinoma                              501   385146   4245789   706915    10590     392427   100579   16599   51195
  KIRC   Kidney renal clear cell carcinoma                                  306   384916   4487756   827668    14184     455287   598701   95277   82497
  KIRP   Kidney renal papillary cell carcinoma                              271   384786   4827856   830528    14986     486170   232041   52484   58017
  LAML   Acute myeloid leukemia                                             122   385529   5121896   408043    10758     283314   22473    606     17201
  LGG    Lower grade glioma                                                 487   385198   4611830   789126    11092     454090   151792   24257   61737
  LIHC   Liver hepatocellular carcinoma                                     367   383962   4152031   449509    9378      272962   127824   28610   46149
  LUAD   Lung adenocarcinoma                                                448   384670   4343043   525439    8848      297745   110266   19790   52156
  LUSC   Lung squamous cell carcinoma                                       359   385034   3676672   598237    10039     334937   191909   44240   60597
  PAAD   Pancreatic adenocarcinoma                                          177   382517   4989296   903193    24432     513599   120777   41820   34727
  PCPG   Pheochromocytoma and paraganglioma                                 175   385235   4701955   589160    19388     385289   34905    2175    23719
  PRAD   Prostate adenocarcinoma                                            479   385067   4801718   1129044   16366     574577   188046   46160   66084
  SARC   Sarcoma                                                            257   382095   4083674   458278    14059     287992   64709    22198   24734
  SKCM   Skin cutaneous melanoma                                            103   384364   4838338   200763    6689      150232   8399     399     6332
  STAD   Stomach adenocarcinoma                                             367   383290   4265676   687004    10723     382962   77711    9612    49489
  TGCT   Testicular germ cell tumors                                        148   385618   4807863   470576    14871     309018   36183    3791    25912
  THCA   Thyroid carcinoma                                                  498   385449   4842972   830377    11908     477575   248274   36261   72317
  THYM   Thymoma                                                            120   385609   4940146   562478    17015     352356   28228    1981    22009
  UCEC   Uterine corpus endometrial carcinoma                               171   385407   4961809   314774    14181     218421   17953    2911    12881

^a^meProbes: methylation probes regulated by meQTLs.

meQTLs in Pancan-meQTL {#SEC3-2}
----------------------

Per cancer type, the associations between each SNP and methylation probe were analyzed for *cis*- and *trans*-meQTL mapping by linear regression with adjusted covariates. In the *cis*-meQTL analysis, we identified a total of 13 619 801 meQTL-CpG pairs at FDR \< 0.05 and \|*r*\| ≥0.3 in 23 cancer types, which corresponded to a median *P*-value \<4.34 × 10^−7^. We found a total of 8 028 964 *cis*-meQTLs across the cancer types, with a median of 318 082 meQTLs per cancer type, and a range from 150 232 in SKCM to 574 577 in prostate adenocarcinoma (PRAD) (Table [1](#tbl1){ref-type="table"}). These meQTLs control DNA methylation at a median of 11 284 CpG sites per cancer type. On average, 35.1% *cis*-meQTLs are associated with multiple CpG sites. In *trans*-meQTL analysis, we identified 3 044 224 meQTL-CpG pairs at FDR \< 0.05 and \|*r*\| ≥0.3 in 23 cancer types, which corresponded to a median of *P*-value \< 1 × 10^−9^. There are 965 050 *trans*-meQTLs, with a median of 46 185 meQTLs per cancer type, and a range from 6332 in SKCM to 82 497 in kidney renal clear cell carcinoma (KIRC) (Table [1](#tbl1){ref-type="table"}).

We further identified 23 432 meQTLs associated with patient overall survival times across different cancer types at FDR \< 0.05. The number of survival-meQTLs ranged from 218 in BRCA to 11 212 in PRAD. We compared meQTL results to GWAS data and found 2 214 458 meQTLs that overlap with GWAS linkage disequilibrium regions of one or multiple traits. Enrichment analyses showed that meQTLs are significant enriched in most of TFBSs, such as CTCF, SIN3AK20 and NRSF ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) and GWAS loci ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}).

WEB DESIGN AND INTERFACE {#SEC4}
========================

The database was built based on Apache, MySQL, PHP and Javascripts (Figure [1C](#F1){ref-type="fig"}). A user-friendly web interface is provided to facilitate searching, browsing and downloading.

Querying meQTLs {#SEC4-1}
---------------

We provide several entries for querying. Pancan-meQTL contains four datasets: *cis*-meQTLs, *trans*-meQTLs, survival-meQTLs and GWAS-meQTLs (Figure [2A](#F2){ref-type="fig"} and [B](#F2){ref-type="fig"}). We developed four corresponding pages to display each dataset (Figure [2A](#F2){ref-type="fig"}). Users can enter each page from the browser bar to query SNPs, methylation data, and methylation-related genes of interest. On the 'home' page, we set a search section for users to query the four meQTL datasets. Also from the home page, users can search results by cancer type from the corresponding cancer type diagram. A quick search option is available on each page (top right) for searching by SNP ID, methylation probe or methylation-related gene symbol. Moreover, we provide a batch search page on the 'Pancan-meQTLs' page (Figure [2C](#F2){ref-type="fig"}). On this page, users can input multiple SNPs, methylation probes or genes of interest. A heatmap will show all the *r* values across all analyzed cancer types. For example, with inputs of 'rs11047888' and 'rs4975682', our results show that rs11044788 has significant correlations with cg11559192 and cg25763538 in 17 and 16 cancer types, respectively; whereas rs4975682 correlates with cg14565270 and cg03265642 in two and six cancer types, respectively (Figure [2D](#F2){ref-type="fig"}).

![Overview of Pancan-meQTL database. (**A**) Browser bar, with a quick search box on the right. (**B**) Four modules in Pancan-meQTL: *cis*-meQTLs, *trans*-meQTLs, survival-associated meQTLs and GWAS-related meQTLs. (**C**) Batch search box allows users to input multiple SNPs, methylation probes and genes of interest. (**D**) Example of heatmap in pancan-meQTLs page showing the correlation coefficient across cancer types. (**E**) Records of *cis*-meQTLs on *cis*-meQTLs page. (**F**) Example of meQTL boxplot. (**G**) Records of survival-meQTLs on survival-meQTLs page. (**H**) Example of a Kaplan--Meier plot on survival-meQTL page.](gky814fig2){#F2}

Querying on the *cis/trans*-meQTL page, a table with SNP ID, SNP genomic position, SNP alleles, methylation probe, methylation position, methylation-related gene symbol, gene position, beta value (effect size of SNP on gene expression), *r* value and *P*-value of meQTL will be returned (Figure [2E](#F2){ref-type="fig"}). For each record, a vector diagram of boxplot is provided to display the association between SNP genotypes and methylation levels (Figure [2F](#F2){ref-type="fig"}).

Querying on the survival-meQTL page, details with SNP ID, SNP genomic position, SNP alleles, log-rank test *P*-value and median survival times of different genotypes will be displayed (Figure [2G](#F2){ref-type="fig"}). A vector diagram of the KM plot is embedded in each record to display the association between SNP genotypes and overall survival times (Figure [2H](#F2){ref-type="fig"}).

Querying on the GWAS-meQTLs page will return the SNP information, related methylation, gene information and related GWAS traits. Search boxes are designed for retrieving specific cancer types, SNP, methylation probe and gene.

Downloading data and figures {#SEC4-2}
----------------------------

All the *cis/trans*-meQTLs for each cancer type can be downloaded from the 'Download' page. The queried results can be downloaded from the query page by clicking the 'Download' button. The *r* values of the batch search can be downloaded from the 'Pancan-meQTL' page. The vector diagrams of the boxplot and KM plot can be downloaded from the *cis/trans*-meQTL and survival-meQTL pages, respectively.

Help section {#SEC4-3}
------------

The 'Help' page provides information for data collection, processing, result summary and contact. Pancan-meQTL welcomes any feedback by email to the address provided in the 'Contact us' section.

CONCLUSION {#SEC5}
==========

We developed Pancan-meQTL as a resource that provides millions of meQTLs in multiple cancer types. Pancan-meQTL is the first public database that focuses on cancer-specific meQTLs. Our comprehensive analyses across 23 cancer types provide a great opportunity to investigate the patterns of meQTLs among cancer types. Among meQTLs, we also identified abundant meQTLs associated with patient survival time or located in known GWAS loci. These meQTLs are potentially promising candidates for genetic research. The Pancan-meQTL database will be continually updated as large-scale genotypic and methylation data become available. As a comprehensive database that characterizes meQTLs across multiple cancer types, Pancan-meQTL will be valuable for improving the interpretation of cancer risk-associated SNPs identified in genetic studies. It represents an important resource for cancer and epigenetic research.

Supplementary Material
======================

###### 

Click here for additional data file.
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